Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O4CV
|
||||
| Former ID |
DIB009258
|
||||
| Drug Name |
Dihydroergotamine nasal
|
||||
| Synonyms |
Dihydroergotamine; Levadex; Tempo Migraine; Inhaled DHE, Sheffield; MAP-0004; Tempo dyhydroergotamine, Sheffield; Nasal DHE (migraine), Britannia; Dihydroergotamine (inhaled, Tempo), MAP; Dihydroergotamine (nasal, migraine), Britannia; Dihydroergotamine (inhaled/oral, Tempo), Sheffield; Dihydroergotamine (migraine,Tempo-inhaled/oral), MAP
|
||||
| Indication | Migraine [ICD9: 346; ICD10:G43] | Approved | [1] | ||
| Therapeutic Class |
Neurology Agents
|
||||
| Company |
Britannia Pharmaceuticals Ltd; allergan; map pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
[C@@]12(N(C(=O)[C@@](O1)(NC(=O)[C@@H]1C[C@H]3[C@H](N(C1<br />)C)Cc1c4c3cccc4[nH]c1)C)[C@H](C(=O)N1[C@H]2CCC1)Cc1cccc<br />c1)O
|
||||
| CAS Number |
CAS 511-12-6
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 1B receptor | Target Info | Modulator | [2] | |
| 5-hydroxytryptamine 1D receptor | Target Info | Modulator | [2] | ||
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapsehsa04024:cAMP signaling pathway | |||||
| Serotonergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| 5HT1 type receptor mediated signaling pathway | |||||
| Reactome | Serotonin receptors | ||||
| G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75. | ||||
| REF 2 | Br J Pharmacol. 1998 Apr;123(8):1655-65.Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.